Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

Effect of Ezetimibe on Gut Microbiota

Phase 4

Recruiting

Conditions: Atherosclerotic Cardiovascular Disease With Dyslipidemia

Interventions: Drug: Atorvastatin 40mg
Drug: Atorvastatin 20mg+Ezetimibe 10mg

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Yonsei University

Target Recruit Count: 110

Registration Number: NCT06784557

Locations: 🇰🇷
Severance hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis Patients

Not Applicable

Recruiting

Conditions: Rhinitis Allergic

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: Yonsei University

Target Recruit Count: 44

Registration Number: NCT06890572

Locations: 🇰🇷
Yonsei University, Seoul, Korea, Republic of

Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease

Phase 4

Recruiting

Conditions: Chronic Ulcer of Lower Extremity
Wound
Botulinum Toxins, Type A
Blood Circulation

Interventions: Drug: Botulinum toxin A

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Yonsei University

Target Recruit Count: 15

Registration Number: NCT06878482

Locations: 🇰🇷
Yongin Severance Hospital, Yongin-si, Gyeonggi-do, Korea, Republic of

Pressure Wire Guidance for Infrapopliteal Artery Interventions

Not Applicable

Not yet recruiting

Conditions: Chronic Limb-Threatening Ischemia

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Yonsei University

Target Recruit Count: 100

Registration Number: NCT06879561

Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring

Phase 3

Not yet recruiting

Conditions: Hypertrophic Cardiomyopathy

First Posted Date: 2025-03-13

Last Posted Date: 2025-03-13

Lead Sponsor: Yonsei University

Target Recruit Count: 100

Registration Number: NCT06873828

Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation

Not Applicable

Not yet recruiting

Conditions: Atrial Fibrillation on Apixaban Treatment

First Posted Date: 2025-03-11

Last Posted Date: 2025-03-11

Lead Sponsor: Yonsei University

Target Recruit Count: 5200

Registration Number: NCT06869083

Locations: 🇰🇷
Division of Cardiology Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Antithrombotic Strategy for AF Patients With High Risk CAD

Not Applicable

Not yet recruiting

Conditions: Atrial Fibrillation
Coronary Artery Disease

Interventions: Drug: Anticoagulation Monotherapy
Drug: Combination therapy

First Posted Date: 2025-03-10

Last Posted Date: 2025-03-14

Lead Sponsor: Yonsei University

Target Recruit Count: 1400

Registration Number: NCT06866665

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Phase 2

Not yet recruiting

Conditions: RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

Interventions: Drug: Amivantamab + FOLFIRI

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-04

Lead Sponsor: Yonsei University

Target Recruit Count: 85

Registration Number: NCT06855849

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)

Interventions: Drug: Experimental treatment arm
Drug: Control treatment arm

First Posted Date: 2025-02-20

Last Posted Date: 2025-04-29

Lead Sponsor: Yonsei University

Target Recruit Count: 141

Registration Number: NCT06837792

Locations: 🇰🇷
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Seoul, Korea, Republic of

ACT-Based Nursing Intervention for Ovarian Cancer Patients: A Pilot Study

Not Applicable

Not yet recruiting

Conditions: Ovarian Neoplasm ; Psychological Distress

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-06

Lead Sponsor: Yonsei University

Target Recruit Count: 25

Registration Number: NCT06813001

Home Terms & Conditions Privacy Policy